Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 10, 2016, Pages 1786-1790

  Druce, Katie L ^a   Bhattacharya, Yagnaseni ^a   Jones, Gareth T ^a   Macfarlane, Gary J ^a   Basu, Neil ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Disease activity; Fatigue; Remission

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; STEROID; THYROXINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DEPRESSION; DISEASE ACTIVITY; FATIGUE; FEMALE; HEALTH STATUS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SHORT FORM 36; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; MIDDLE AGED; REGISTER;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84991058648     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew241     Document Type: Article

References (21)

1. Hewlett S, Nicklin J, Treharne GJ. Fatigue in musculoskeletal conditions. Reports on the Rheumatic Diseases (Series 6). Topical Rev 2008;1:1-11.
2. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:2750-62.
3. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
4. Druce K, Jones GT, Macfarlane GJ, Verstappen SMM, Basu N. The longitudinal course of fatigue in rheumatoid arthritis-results from the Norfolk Arthritis Register. J Rheumatol 2015;42:2059-65.
5. Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology 2012;51:60-8.
6. Druce KL, Jones GT, Macfarlane GJ, Basu N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology 2015;54:964-71.
7. Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64:iv42-3.
8. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Care Res 2007;57:429-39.
10. Flüß E, Bond CM, Jones GT, Macfarlane GJ. The reevaluation of the measurement of pain in populationbased epidemiological studies: the SHAMA study. Br J Pain 2015;9:134-41.
11. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78.
12. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009;35:745-57, vii-viii.
13. Bruce B, Fries J. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
14. Hyrich KL, Watson KD, Silman AJ et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
15. Hewlett S, Chalder T, Choy E et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology 2011;50:1004-6.
16. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology 2010;49:1294-302.
17. Jump RL, Fifield J, Tennen H, Reisine S, Giuliano AJ. History of affective disorder and the experience of fatigue in rheumatoid arthritis. Arthritis Care Res 2004;51:239-45.
18. LaRochelle J, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993;95:258-64.
19. Ingles JL, Eskes GA, Phillips SJ. Fatigue after stroke. Arch Phys Med Rehabil 1999;80:173-8.
20. Hewlett S, Cockshott Z, Byron M et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Care Res 2005;53:697-702.
21. Kirwan JR, Minnock P, Adebajo A et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-7.